OKYO Pharma

NAQ:OKYO · GG00BMFG5F62

BiotechnologyX-Small

360° View

Value74

Price/Sales—

Price/Earnings84

Price/Book94

Dividend Yield1

Growth41

Revenue Growth—

Profit Growth29

Capital Growth82

TSR 52w33

Safety10

Leverage55

Liquidity20

Refinancing12

Combined36

Sentiment50

Analyst Opinions57

Pro Holdings32

Opinion Changes50

Market Pulse59

Profile

CountryUK

IndustryBiotechnology

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Founded2007

Employees9

Websiteokyopharma.com

ISINGG00BMFG5F62

Last UpdateApr 2, 2026

Index & Theme

OphthalmologyPain ManagementNeurologyInflammationAllergyBiotechnologyHealth CareMedicalPharmaceutical

Description

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. The company’s research program focuses on a novel G Pr…

Analysis

OKYO Pharma's 360° View rank of 40 places it below its peer average — better than 40% of its true peers.

It's growing slowly (41) and reasonably valued (74). On safety it is highly leveraged (10), and the market shows muted sentiment (50). Taken together, its Combined rank of 36 reads as below its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare OKYO Pharma with its peers

GH Research

NMQ:GHRS

CountryIreland

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

NewAmsterdam Pharma Company

NMQ:NAMS

CountryNetherlands

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Pharming

AEX:PHARM

CountryNetherlands

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Pentixapharm

GER:PTP

CountryGermany

IndustryHealth Care Equipment & Supplies

SizeX-Small

Full Stock Analysis →

PolyPid

NAQ:PYPD

CountryIsrael

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Mediwound

NMQ:MDWD

CountryIsrael

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →